AMENDMENTS TO THE CLAIMS:

1. (Currently Amended) A method for treating a CNS disorder or impaired cognitive performance in a subject comprising administering to said subject in need thereof an effective amount of a pharmaceutical composition comprising a compound or a stereoisomer, pharmaceutically acceptable salt, solvate or polymorph thereof according to the structure:



or



(I) (II)

wherein:

R^1 and R^2 are independently selected from H, C_1-C_3alkyl, F, Cl, Br, I, OH, O(C_1-C_6alkyl), O-C(=O)-(C_1-C_6)alkyl or C(=O)-O-(C_1-C_6)alkyl;

R^3 is H or a C_1-C_6alkyl group;

R^4, R^5, R^6, R^7 and R^8 are independently selected from H, C_1-C_6 alkyl, F, Cl, Br, I, OH, -$(CH_2)_n$O(C_1-C_6alkyl), -$(CH_2)_n$O-C(=O)-(C_1-C_6) alkyl or -$(CH_2)_n$C(=O)-O-(C_1-C_6) alkyl;

R^9 and R^{10} are independently H, C_1-C_6 alkyl or together form a –$(CH_2)_m$- group to produce a 5-7 membered ring;

N is from 0 to 5;

M is from 0 to 3;

and ~~A-~~ A$^-$ is a pharmaceutically acceptable anion of a pharmaceutical salt, which forms a salt with the quaternized amine group, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

2. (Original) A method of claim 1 wherein R^1 and R^2 are both OCH_3 groups, R^3 is a CH_3 group, R^4, R^5, R^6, R^7 and R^8 are each H, R^9 and R^{10} are each H, CH_3 or together form a -CH_2- group to produce a five-membered ring;

and A^- is Cl-, citrate or phosphate.

3. (Original) A method of claim 2, wherein R^9 and R^{10} together form a -CH_2- group to produce a five-membered ring.

4. (Original) A method of claim 1, wherein the CNS disorder is a bipolar disorder.

5. (Original) A method of claim 1, wherein the CNS disorder is an anxiety disorder.

6. (Original) A method of claim 1, wherein the CNS disorder is stress-induced.

7. (Currently Amended) A method of claim_1, wherein the CNS disorder is attention deficit hyperactivity disorder (ADHD).

8. (Original) A method of claim 1, wherein the CNS disorder is schizophrenia.

9. (Original) A method of claim 1, wherein said subject is treated for impaired cognitive performance.

10. (Original) A method of claim 1, wherein the CNS disorder is associated with enhanced PKC activity.

11. (Original) A method of claim ~~1~~9, wherein the impaired cognitive performance is induced or exacerbated by stress.

12. (Original) A method of claim 1, wherein the pharmaceutical composition is administered orally and the subject is a human.

13. (Original) A method of claim 9, wherein the pharmaceutical composition is administered orally and the subject is a human.

14. (Original) A method of claim 10, wherein the pharmaceutical composition is administered orally and the subject is a human.

15.–17. (Canceled)

18. (Original) A method of treatment comprising administering to a subject suffering from

manic episodes associated with enhanced PKC activity a therapeutically effective amount of a composition according to claim 15.

19. (Original) A method of claim 18, wherein the manic episodes are also stress induced.

20. (Original) A method comprising protecting a subject from developing a CNS disorder by administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 15.

21. (New) A method of Claim 1, wherein the CNS disorder is bipolar disorder, schizophrenia, an anxiety disorder, impaired cognitive performance, or attention deficit hyperactivity disorder (ADHD).